Transplanting Older Patients with TP53 Mutated Disease

TP53 mutated MDS and AML represent some of the most difficult diseases to treat, with poor prognosis. Although allogeneic stem cell transplant has the potential to cure myeloid malignancies, cure rates in TP53 mutated disease are low, and the utility of transplant for such patients is controversial. In this webinar, we will use a case based approach to debate the best transplant approach (including no transplant) for older patients with TP53 mutated disease in different scenarios. 

Presented by the ASTCT Aging SIG

Speakers:

Mariam Nawas, MD, University of Chicago Medical Center 
Pashna Munshi, MD, University of Pennsylvania
Mohamed Sorror, MD, Fred Hutchinson Cancer Center
Jacqueline Garcia, MD, Dana-Farber Cancer Institute
Mikkael Sekeres, MD, University of Miami

Moderator:

Rebecca Olin, MD MSCE, University of California San Francisco